Novartis pauses study of GenVec's gene therapy

GenVec Inc. (NASDAQ:GNVC) slid $1.02 (59%) to $0.72 on Monday after disclosing in a regulatory filing that partner Novartis AG (NYSE:NVS; SIX:NOVN) notified

Read the full 235 word article

User Sign In